Stock Ratings / Health Care / AYTU / dividends

BYSI (42) TXMD (48) ATOS (36) QNTM (58) ⌘ Pro Terminal →

Aytu BioPharma Inc. (AYTU) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.98 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Aytu BioPharma Inc. (AYTU) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $21.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AYTU)Realized 20D OHLCV Swing Band: ±9.5%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AYTU)

✓Walkthrough of AYTU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AYTU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.26%▼ DESCENDING CHANNEL

2026-10-30O $1.98H $2.02L $1.90C $1.98VOL 97.3K

RES: $2.25SUP: $1.79SMA50: $2.10SMA200: $2.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AYTU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AYTU Butterfly Map → + Track AYTU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AYTU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AYTU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AYTU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AYTU)

Health Care Rank #623 of 1016 ⚔️ BYSI vs AYTU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AYTU vs. BYSI, TXMD, ATOS, QNTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aytu BioPharma Inc. (AYTU) ranks #623 by composite RQD confidence (41/100, grade D-) and #826 by equity capitalization ($21.5M). Within this direct 5-issuer industry benchmark cohort, AYTU leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with AYTU at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AYTU ACTIVE Aytu BioPharma Inc.	D-	41/100	—	69.0%	-35.0%	+0.51%	$21.5M	Benchmark Subject
BYSI BeyondSpring Inc.	D-	42/100	—	—	-35.0%	-1.49%	$21.2M	/bysi-vs-aytu →
TXMD TherapeuticsMD Inc.	D	48/100	—	—	-12.9%	+2.24%	$21.2M	/txmd-vs-aytu →
ATOS Atossa Therapeutics Inc.	D-	36/100	—	—	-35.0%	-5.91%	$22.3M	/atos-vs-aytu →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-aytu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001385818

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Aytu BioPharma Inc. (AYTU) reported GAAP revenue of $66.4M (+1.8% vs. FY2024 revenue of $65.2M , and -38.2% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$1.9M, and free cash flow of -$2.2M (-26.1% YoY). On the balance sheet, AYTU closed FY2025 with $122.0M in total assets against $10.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$66.4M	-$13.6M	-$1.9M	-$2.2M	$122.0M	$10.0M
FY2024 (FY)	2024-06-30	$65.2M	-$15.8M	-$1.4M	-$1.7M	$116.2M	$10.0M
FY2023 (FY)	2023-06-30	$107.4M	-$17.1M	-$5.1M	-$5.1M	—	—

3. AYTU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AYTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aytu BioPharma Inc. (NASDAQ: AYTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.98 (+0.51% 1D, market cap $21.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AYTU ranks #623 in composite RQD confidence.

How does AYTU compare to BYSI and TXMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AYTU carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 69.0%, and ROIC of -35.0%. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M) and TXMD (TherapeuticsMD Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -12.9%, cap $21.2M). Among the 5-stock peer group, AYTU leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AYTU?

Per AYTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001385818), Aytu BioPharma Inc. generated $66.4M in revenue (+1.8% YoY), -$13.6M in net income, and -$2.2M in free cash flow against $122.0M in total assets and $10.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AYTU trading relative to its 50-day, 200-day, and 52-week technical levels?

AYTU last traded at $1.98 (+0.51% on volume of 9,467 shares), positioning the stock -5.71% below its 50-day simple moving average ($2.10) and -14.66% below its 200-day simple moving average ($2.32). Across its 52-week range of $1.80 to $3.07, AYTU sits at the 14.2% percentile with a 14-day RSI of 42.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($1.79 to $2.17).

AYTU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does AYTU pay a dividend and is it safe?

Aytu BioPharma Inc. (AYTU) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: AYTU RQD Cockpit AYTU 12M Forecast AYTU Earnings & Move AYTU Dividends & DRIP AYTU Insiders & 13F AYTU Whale Options AYTU Profit Sankey AYTU News & Why